Oral semaglutide was associated with more pronounced cardiovascular benefits among patients with higher baseline HbA1c in type 2 diabetes.

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

* Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new ...

Imagine a future where the global incident cases of liver cancer almost doubles, rising from 870 000 cases in 2022 to over ...

Researchers warn that the public, policy makers and even clinicians are not aware of the growing problem of liver cancer.

Explore the potential of GLP-1 receptor agonists for rheumatoid arthritis. Learn about their safety, benefits, and what to consider before starting these medications.

There's been plenty of buzz about this class of drug, following publication of a high-profile trial this year. How much do we ...

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type 2 diabetes.

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor ...

Compared with other antidiabetic drugs, semaglutide is associated with a lower risk for Alzheimer disease-related dementia in patients with type 2 diabetes.

Powerful new medications such as Ozempic and Mounjaro, known as GLP-1 drugs are helping to win the war against obesity in ...

Once scorned as a cosmetic lifestyle disfigurement, obesity today is recognised as a chronic and progressive disease. From ...